Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 2,261.4	$ 1,331.2
Marketable securities	1,541.1	1,278.9
Accounts receivable, net	1,549.4	1,913.8
Due from anti-CD20 therapeutic programs	412.3	413.5
Inventory	1,351.5	1,068.6
Other current assets	740.8	881.1
Total current assets	7,856.5	6,887.1
Marketable securities	892.0	772.1
Property, plant and equipment, net	3,416.4	3,411.5
Operating lease assets	375.4	433.3
Intangible assets, net	2,221.3	3,084.3
Goodwill	5,761.1	5,762.1
Deferred tax asset	1,415.1	1,369.5
Investments and other assets	1,939.5	2,899.0
Total assets	23,877.3	24,618.9
Current liabilities:
Current portion of notes payable	999.1	0.0
Taxes payable	174.7	142.0
Accounts payable	589.2	454.9
Accrued expense and other	2,535.2	3,145.3
Total current liabilities	4,298.2	3,742.2
Notes payable	6,274.0	7,426.2
Deferred tax liability	694.5	1,032.8
Long-term operating lease liabilities	330.4	402.0
Other long-term liabilities	1,320.5	1,329.6
Total liabilities	12,917.6	13,932.8
Commitments, contingencies and guarantees (Notes 21 and 22)
Biogen Inc. shareholders’ equity
Preferred stock, par value $0.001 per share	0.0	0.0
Common stock, par value $0.0005 per share	0.1	0.1
Additional paid-in capital	68.2	0.0
Accumulated other comprehensive loss	(106.7)	(299.0)
Retained earnings	13,911.7	13,976.3
Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively	(2,977.1)	(2,977.1)
Total Biogen Inc. shareholders’ equity	10,896.2	10,700.3
Noncontrolling interests	63.5	(14.2)
Total equity	10,959.7	10,686.1
Total liabilities and equity	$ 23,877.3	$ 24,618.9